vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $53.00 Consensus Target Price from Brokerages

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have received an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $55.3333.

VTVT has been the subject of a number of research analyst reports. Zacks Research downgraded shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Evercore began coverage on vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target for the company. Rodman & Renshaw began coverage on vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Finally, Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in VTVT. Baker BROS. Advisors LP boosted its stake in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $221,000. 683 Capital Management LLC bought a new position in shares of vTv Therapeutics in the fourth quarter worth approximately $731,000. Finally, Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Price Performance

Shares of VTVT opened at $35.40 on Monday. The firm’s 50 day simple moving average is $33.69 and its 200 day simple moving average is $35.71. The company has a market capitalization of $139.48 million, a P/E ratio of -38.06 and a beta of 0.25. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $20.00 million. On average, equities analysts anticipate that vTv Therapeutics will post -2.19 earnings per share for the current year.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.